diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12412diaendo-12412Research ArticleОбзорыReviewУратснижающие эффекты ингибиторов дипептидилпепти-дазы-4Urate-lowering effects of dipeptidyl peptidase-4 inhibitorshttps://orcid.org/0000-0002-5290-156XПаневинТарас СергеевичPanevinTaras S.

Врач, eLibrary SPIN: 7839-3145.

115522, Москва, Каширское ш., д. 34А

MD, eLibrary SPIN: 7839-3145.

34A Kashirskoe Shosse, 115522 Moscow

tarasel@list.ruhttps://orcid.org/0000-0002-5394-7869ЖелябинаОльга ВладимировнаZhelyabinaOlga V.

Желябина Ольга Владимировна, младший научный сотрудник, eLibrary SPIN: 8038-6195.

Москва

MD, junior research associate, eLibrary SPIN: 8038-6195.

Moscow

olga-sheliabina@mail.ruhttps://orcid.org/0000-0003-1191-5831ЕлисеевМаксим СергеевичEliseevMaxim S.

Кандидат медицинских наук, eLibrary SPIN: 2524-7320.

Москва

MD, PhD, eLibrary SPIN: 2524-7320.

Moscow

elicmax@rambler.ruhttps://orcid.org/0000-0002-5057-127XШестаковаМарина ВладимировнаShestakovaMarina V.

Доктор медицинских наук, профессор, академик РАН, eLibrary SPIN: 3482-7651.

Москва

MD, PhD, Professor, eLibrary SPIN: 3482-7651.

Moscow

nephro@endocrincentr.ruНаучно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202002122020234349356Copyright © Паневин Т.С., Желябина О.В., Елисеев М.С., Шестакова М.В., 20202020Паневин Т.С., Желябина О.В., Елисеев М.С., Шестакова М.В.Panevin T.S., Zhelyabina O.V., Eliseev M.S., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12412

Гиперурикемия представляет собой увеличение концентрации мочевой кислоты (МК) в сыворотке крови >420 мкмоль/л у мужчин или >360 мкмоль/л у женщин и является распространенным биохимическим отклонением. Она отражает перенасыщение внеклеточной жидкости уратами, концентрация которых превышает предел их растворимости, что предрасполагает к формированию кристаллов натриевой соли МК и в результате - развитию подагры, мочекаменной болезни и других заболеваний. В ранее проведенных исследованиях отмечены частое сочетание и взаимосвязь пуринового и углеводного обменов. В связи с этим выбор препаратов для коррекции данных нарушений должен учитывать возможность сочетанного положительного влияния на уровень МК и глюкозы сыворотки. Особый интерес представляют сахароснижающие препараты с плейотропным влиянием на несколько компонентов метаболического синдрома. На сегодняшний день одной из самых часто назначаемых групп препаратов в терапии сахарного диабета 2 типа являются влияющие на уровень инкретинов ингибиторы дипептидилпептидазы-4 ( глиптины), которые могут быть потенциально привлекательными у пациентов с нарушением пуринового обмена, поскольку имеющиеся данные говорят о наличии у данных препаратов влияния на уровень МК.

Hyperuricemia is an increase of uric acid (UA) concentration in blood serum >420 pmol/L in men or >360 pmol/L in women and is considered to be a common biochemical abnormality. This condition shows that the extracellular fluid is oversaturated with urates, which concentration exceeds the limit of their solubility. This fact predisposes to the formation of crystals of sodium salt of UA and results in gout, urolithiasis, and other diseases. The frequent combination and relationship between purine and carbohydrate metabolism were noted in previous studies. In this regard, the choice of drugs for correcting these disorders should consider the possibility of a combined positive effect on the UA and serum glucose levels. The hypoglycemic drugs with pleiotropic effects on several metabolic syndrome components are considered to be of particular interest. Currently, one of the most frequently prescribed groups of drugs in the treatment of diabetes mellitus type 2 are dipeptidyl peptidase-4 inhibitors, which affect the level of incretins (gliptins). These drugs can be potentially attractive in patients with purine metabolism disorders since the available data indicate that these drugs affect UA level.

подаграгиперурикемиямочевая кислотасахарный диабет 2 типаинсулинорезистентностьингибиторы дипептидилпептидазы 4линаглиптинgouthyperuricemiauric acidtype 2 diabetesinsulin resistanceDPP4 inhibitorslinagliptinПоисково-аналитическая работа и подготовка статьи осуществлены на личные средства авторского коллективаReferencesЖелябина О.В., Елисеев М.С. Ингибиторы ксантиноксидазы при асимптоматической гиперурикемии // Современная ревматология. — 2019. — Т. 13. — №4. — С. 137-142. doi: https://doi.org/10.14412/1996-7012-2019-4-137-142Zhelyabina OV, Eliseev MS. Xanthine oxidase inhibitors in asymptomatic hyperuricemia. Modern rheumatologyjournal. 2019;13(4):137-142. (In Russ.) doi: https://doi.org/10.14412/1996-7012-2019-4-137-142Shiozawa A, Szabo SM, Bolzani A, et al. Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 2017;44(3):388-396. doi: https://doi.org/10.3899/jrheum.160452Shiozawa A, Szabo SM, Bolzani A, et al. Serum uric acid and the risk of incident and recurrent gout: a systematic review. J Rheumatol. 2017;44(3):388-396. doi: https://doi.org/10.3899/jrheum.160452Abbasian M, Ebrahimi H, Delvarianzadeh M, et al. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016;10(3):132-136. doi: https://doi.org/10.1016/j.dsx.2016.01.003Abbasian M, Ebrahimi H, Delvarianzadeh M, et al. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016;10(3):132-136. doi: https://doi.org/10.1016/j.dsx.2016.01.003Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207. doi: https://doi.org/10.1186/s12872-016-0379-zZuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207. doi: https://doi.org/10.1186/s12872-016-0379-zRichette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2019;79(1):31-38. doi: https://doi.org/10.1136/annrheumdis-2019-215315Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2019;79(1):31-38. doi: https://doi.org/10.1136/annrheumdis-2019-215315Елисеев М.С. Подагра. В кн.: Насонов Е.Л. Ревматология. Российские клинические рекомендации. — М.: ГЭОТАР-Медиа, 2017. — С. 253-264.Eliseev MS. Podagra. In: Nasonov EL. Revmatologiya. Rossiyskiye klinicheskiye rekomendatsii. Moscow: GEOTAR-Media; 2017. P 253-264. (In Russ.)Барскова В.Г., Елисеев М.С., Кудаева Ф.М., и др. Влияние метформина на течение подагры и инсулинорезистентность // Клиническая медицина. — 2009. — Т. 87. — №7. — С. 41-46.Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformine on the clinical course of gout and insulin resistance. Clinical medicine. 2009;87(7):41-46. (In Russ.)Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой // Терапевтический архив. — 2020. — Т. 92. — №5. — С. 110-118. doi: https://doi.org/10.26442/00403660.2020.05.000633Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic archive. 2020;92(5):110-118. (In Russ.) doi: https://doi.org/10.26442/00403660.2020.05.000633Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of Type 2 diabetes: a prospective study. Am J Med. 2010;123(10):957-961. doi: https://doi.org/10.1016/j.amjmed.2010.03.027Bhole V, Choi JW, Kim SW, et al. Serum uric acid levels and the risk of Type 2 diabetes: a prospective study. Am J Med. 2010;123(10):957-961. doi: https://doi.org/10.1016/j.amjmed.2010.03.027Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi: https://doi.org/10.1002/art.22466Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. doi: https://doi.org/10.1002/art.22466Елисеев М.С., Барскова В.Г. Нарушения углеводного обмена при подагре: частота выявления и клинические особенности // Терапевтический архив. — 2010. — Т. 82. — №5. — С. 50-54.Eliseev MS, Barskova VG. Carbohydrate metabolic disturbances in gout: Detection rate and clinical features. Therapeutic Archive. 2010;82(5):50-54. (In Russ.)Choi BG, Kim DJ, Baek MJ, et al. Hyperuricaemia and development of type 2 diabetes mellitus in Asian population. Clin Exp Pharmacol Physiol. 2018;45(6):499-506. doi: https://doi.org/10.1111/1440-1681.12911Choi BG, Kim DJ, Baek MJ, et al. Hyperuricaemia and development of type 2 diabetes mellitus in Asian population. Clin Exp Pharmacol Physiol. 2018;45(6):499-506. doi: https://doi.org/10.1111/1440-1681.12911Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: https://doi.org/10.1186/1471-2369-15-122Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: https://doi.org/10.1186/1471-2369-15-122Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with Type 2 diabetes mellitus. PLoSONE. 2011;6(11):e27817. doi: https://doi.org/10.1371/journal.pone.0027817Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with Type 2 diabetes mellitus. PLoSONE. 2011;6(11):e27817. doi: https://doi.org/10.1371/journal.pone.0027817Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197-3204. doi: https://doi.org/10.1096/fj.13-247148Choi YJ, Yoon Y, Lee KY, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 2014;28(7):3197-3204. doi: https://doi.org/10.1096/fj.13-247148Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145-4151. doi: https://doi.org/10.2174/138161205774913255Glantzounis G, Tsimoyiannis E, Kappas A, Galaris D. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145-4151. doi: https://doi.org/10.2174/138161205774913255Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69(6):1036-1044. doi: https://doi.org/10.1161/hypertensionaha.116.08998Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. Hypertension. 2017;69(6):1036-1044. doi: https://doi.org/10.1161/hypertensionaha.116.08998Fonseca VA. Defining and characterizing the progression of Type 2 diabetes. Diabetes Care. 2009;32(suppl_2):S151-S156. doi: https://doi.org/10.2337/dc09-s301Fonseca VA. Defining and characterizing the progression of Type 2 diabetes. Diabetes Care. 2009;32(suppl_2):S151-S156. doi: https://doi.org/10.2337/dc09-s301Zhang Y, Wei F, Chen C, et al. Higher triglyceride level predicts hyperuricemia: A prospective study of 6-year follow-up. J Clin Lipidol. 2018;12(1):185-192. doi: https://doi.org/10.1016/jJacl.2017.10.009Zhang Y, Wei F, Chen C, et al. Higher triglyceride level predicts hyperuricemia: A prospective study of 6-year follow-up. J Clin Lipidol. 2018;12(1):185-192. doi: https://doi.org/10.1016/jJacl.2017.10.009Елисеев М.С., Насонов Е.Л. Применение канакинумаба при подагре // Научно-практическая ревматология. — 2018. — Т.56. — С. 41-48. doi: https://doi.org/10.14412/1995-4484-2018-41-48Eliseev MS, Nasonov EL.Therapy with canakinumab for gout. Rheumatology science and practice. 2018;56:41-48. (In Russ.). doi: https://doi.org/10.14412/1995-4484-2018-41-48Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study. Ann Rheum Dis. 2014;74(9):1651-1658. doi: https://doi.org/10.1136/annrheumdis-2014-205337Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study. Ann Rheum Dis. 2014;74(9):1651-1658. doi: https://doi.org/10.1136/annrheumdis-2014-205337Rodrfguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis. 2010;69(12):2090-2094. doi: https://doi.org/10.1136/ard.2010.130013Rodrfguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis. 2010;69(12):2090-2094. doi: https://doi.org/10.1136/ard.2010.130013Chen W, Liu X, Ye S. Effects of metformin on blood and urine proinflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34. doi: https://doi.org/10.1186/s12950-016-0142-3Chen W, Liu X, Ye S. Effects of metformin on blood and urine proinflammatory mediators in patients with type 2 diabetes. J Inflamm (Lond). 2016;13:34. doi: https://doi.org/10.1186/s12950-016-0142-3Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197-201. doi: https://doi.org/10.1007/bf00577838Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197-201. doi: https://doi.org/10.1007/bf00577838Lambeir AM, Durinx C, Scharpe S, de Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294. doi: https://doi.org/10.1080/713609354Lambeir AM, Durinx C, Scharpe S, de Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294. doi: https://doi.org/10.1080/713609354Deacon CF. Therapeutic Strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181-2189. doi: https://doi.org/10.2337/diabetes.53.9.2181Deacon CF. Therapeutic Strategies based on glucagon-like peptide 1. Diabetes. 2004;53(9):2181-2189. doi: https://doi.org/10.2337/diabetes.53.9.2181Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP Gastroenterology. 2007;132(6):2131-2157. doi: https://doi.org/10.1053/j.gastro.2007.03.054Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP Gastroenterology. 2007;132(6):2131-2157. doi: https://doi.org/10.1053/j.gastro.2007.03.054Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25(8):1963-1972. doi: https://doi.org/10.1185/03007990903094361Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25(8):1963-1972. doi: https://doi.org/10.1185/03007990903094361Yamauchi K, Sato Y, Yamashita K, et al. RS3PE in association with dipeptidyl peptidase-4 Inhibitor: report of two cases. Diabetes Care. 2012;35(2):e7. doi: https://doi.org/10.2337/dc11-1995Yamauchi K, Sato Y, Yamashita K, et al. RS3PE in association with dipeptidyl peptidase-4 Inhibitor: report of two cases. Diabetes Care. 2012;35(2):e7. doi: https://doi.org/10.2337/dc11-1995McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with Type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2012;36(2):237-244. doi: https://doi.org/10.2337/dc12-0706McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with Type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2012;36(2):237-244. doi: https://doi.org/10.2337/dc12-0706Weihofen WA, Liu J, Reutter W, et al. Crystal Structure of CD26/Dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem. 2004;279(41):43330-43335. doi: https://doi.org/10.1074/jbc.m405001200Weihofen WA, Liu J, Reutter W, et al. Crystal Structure of CD26/Dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface. J Biol Chem. 2004;279(41):43330-43335. doi: https://doi.org/10.1074/jbc.m405001200Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem. 1995;270(32):18797-18803. doi: https://doi.org/10.1074/jbc.270.32.18797Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem. 1995;270(32):18797-18803. doi: https://doi.org/10.1074/jbc.270.32.18797Itou M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298-2306. doi: https://doi.org/10.3748/wjg.v19.i15.2298Itou M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298-2306. doi: https://doi.org/10.3748/wjg.v19.i15.2298Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-838. doi: https://doi.org/10.1172/jci34275Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-838. doi: https://doi.org/10.1172/jci34275Исмаилова Г.А. Влияние ингибиторов дипептидилпептидазы-4 на показатели липидного обмена у пациентов с сахарным диабетом 2-го типа в сочетании с метаболическим синдромом // Кардиология в Беларуси. — 2016. — №1. — С. 138-147Ismailova GA. Vliyanie ingibitorov dipeptidilpeptidazy-4 na pokazateli lipidnogo obmena u patsientov s sakharnym diabetom 2-go tipa v sochetanii s metabolicheskim sindromom. Kardiologiya vBelarusi. 2016;(1):138-147. (In Russ.)Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017;59(1):R1-R10. doi: https://doi.org/10.1530/jme-17-0005Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017;59(1):R1-R10. doi: https://doi.org/10.1530/jme-17-0005Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology. 2014;155(6):2266-2276. doi: https://doi.org/10.1210/en.2013-1920Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology. 2014;155(6):2266-2276. doi: https://doi.org/10.1210/en.2013-1920Stange T, Kettmann U, Holzhausen HJ. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur J Histochem. 2000;44(2):157-164.Stange T, Kettmann U, Holzhausen HJ. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. Eur J Histochem. 2000;44(2):157-164.Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207. doi: https://doi.org/10.1007/s11154-014-9287-7Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207. doi: https://doi.org/10.1007/s11154-014-9287-7Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl saltsensitive rats. J Hypertens. 2003;21(6):1 125-1135. doi: https://doi.org/10.1097/00004872-200306000-00012Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl saltsensitive rats. J Hypertens. 2003;21(6):1 125-1135. doi: https://doi.org/10.1097/00004872-200306000-00012Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. MicrovascRes. 2012;84(3):395-398. doi: https://doi.org/10.1016/j.mvr.2012.06.008Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. MicrovascRes. 2012;84(3):395-398. doi: https://doi.org/10.1016/j.mvr.2012.06.008Kusunoki M, Natsume Y, Miyata T, et al. Effects of concomitant administration of a Dipeptidyl Peptidase-4 inhibitor in Japanese patients with Type 2 diabetes showing relatively good glycemic control under treatment with a sodium glucose CoTransporter 2 inhibitor. Drug Res (Stuttg). 2018;68(12):704-709. doi: https://doi.org/10.1055/a-0585-0145Kusunoki M, Natsume Y, Miyata T, et al. Effects of concomitant administration of a Dipeptidyl Peptidase-4 inhibitor in Japanese patients with Type 2 diabetes showing relatively good glycemic control under treatment with a sodium glucose CoTransporter 2 inhibitor. Drug Res (Stuttg). 2018;68(12):704-709. doi: https://doi.org/10.1055/a-0585-0145Conlon BA, Law WR. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol. 2004;138(1):14-20. doi: https://doi.org/10.1111/j.1365-2249.2004.02591.xConlon BA, Law WR. Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses. Clin Exp Immunol. 2004;138(1):14-20. doi: https://doi.org/10.1111/j.1365-2249.2004.02591.xKlemann C, Wagner L, Stephan M, von Horsten S. Cut to the chase: a review of CD26 / dipeptidyl peptidase-4’ s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21. doi: https://doi.org/10.1111/cei.12781Klemann C, Wagner L, Stephan M, von Horsten S. Cut to the chase: a review of CD26 / dipeptidyl peptidase-4’ s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21. doi: https://doi.org/10.1111/cei.12781Lin CH, Lin CC. Sitagliptin attenuates inflammatory responses in lipopolysaccharide - stimulated cardiomyocytes via nuclear factor-kB pathway inhibition. Exp TherMed. 2016;11(6):2609-2615. doi: https://doi.org/10.3892/etm.2016.3255Lin CH, Lin CC. Sitagliptin attenuates inflammatory responses in lipopolysaccharide - stimulated cardiomyocytes via nuclear factor-kB pathway inhibition. Exp TherMed. 2016;11(6):2609-2615. doi: https://doi.org/10.3892/etm.2016.3255Kabel AM, Omar MS, Alhadhrami A, et al. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-P1, NF-kB and glucagon-like peptide 1. PhysiolBehav. 2018;188:108-118. doi: https://doi.org/10.1016/j.physbeh.2018.01.028Kabel AM, Omar MS, Alhadhrami A, et al. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-P1, NF-kB and glucagon-like peptide 1. PhysiolBehav. 2018;188:108-118. doi: https://doi.org/10.1016/j.physbeh.2018.01.028Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;19(1):133-140. doi: https://doi.org/10.1517/13543780903463862Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;19(1):133-140. doi: https://doi.org/10.1517/13543780903463862Heise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-794. doi: https://doi.org/10.1111/j.1463-1326.2009.01046.xHeise T, Graefe-Mody EU, Huttner S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11(8):786-794. doi: https://doi.org/10.1111/j.1463-1326.2009.01046.xYamagishi S, Ishibashi Y, Ojima A, et al. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol. 2014;176(2):550-552. doi: https://doi.org/10.1016/jjjcard.2014.07.023Yamagishi S, Ishibashi Y, Ojima A, et al. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol. 2014;176(2):550-552. doi: https://doi.org/10.1016/jjjcard.2014.07.023Darsalia V, Ortsater H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2012;62(4):1289-1296. doi: https://doi.org/10.2337/db12-0988Darsalia V, Ortsater H, Olverling A, et al. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2012;62(4):1289-1296. doi: https://doi.org/10.2337/db12-0988Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119-130. doi: https://doi.org/10.1159/000341487Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119-130. doi: https://doi.org/10.1159/000341487Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014;46(10):717-721. doi: https://doi.org/10.1055/s-0034-1371892Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res. 2014;46(10):717-721. doi: https://doi.org/10.1055/s-0034-1371892Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. JHypertens. 2014;32(11):2211-2223. doi: https://doi.org/10.1097/hjh.0000000000000328Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. JHypertens. 2014;32(11):2211-2223. doi: https://doi.org/10.1097/hjh.0000000000000328Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120-2131. doi: https://doi.org/10.2337/db13-1029Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120-2131. doi: https://doi.org/10.2337/db13-1029Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90(4):783-796. doi: https://doi.org/10.1016/j.kint.2016.06.012Takashima S, Fujita H, Fujishima H, et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90(4):783-796. doi: https://doi.org/10.1016/j.kint.2016.06.012Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA. 2019;321(1):69-79. doi: https://doi.org/10.1001/jama.2018.18269Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with Type 2 diabetes and high cardiovascular and renal risk: the carmelina randomized clinical trial. JAMA. 2019;321(1):69-79. doi: https://doi.org/10.1001/jama.2018.18269McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with Type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139(3):351-361. doi: https://doi.org/10.1161/circulationaha.118.038352McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with Type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation. 2019;139(3):351-361. doi: https://doi.org/10.1161/circulationaha.118.038352Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in Type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304-2310. doi: https://doi.org/10.2337/dc16-1415Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in Type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304-2310. doi: https://doi.org/10.2337/dc16-1415Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10):1171-1178. doi: https://doi.org/10.1177/0091270008323753Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48(10):1171-1178. doi: https://doi.org/10.1177/0091270008323753

The authors declare that there are no conflicts of interest present.